肺神经内分泌肿瘤分类的临床病理挑战与未来临床实践靶点
本文综述肺神经内分泌肿瘤(NEN)分类中的关键临床病理问题与信息性分子标志物,包括低级别NEN根治性切除后首选结局指标、WHO分类联合Ki-67及OTP/CD44的预后价值、活检标本中典型与非典型类癌诊断的意义、LCNEC与SCLC形态学分离及RB1/pRb与NAPY转录因子预测全身治疗结局的价值,以及活检标本中LCNEC与NSCLC鉴别所需额外诊断标准;提出应调整NEN分类纳入可用于活检标本的预后和预测标志物以指导治疗结局驱动分类。
要点
- 低级别NEN根治性切除后首选结局指标(总生存或无复发生存间期)尚待明确。
- WHO分类联合Ki-67及OTP、CD44等分子标志物可能改善低级别NEN预后判断。
- 活检标本诊断类癌困难,转移性类癌核分裂率可从典型向非典型及高级别NEN升高。
核心结论
- 应调整肺NEN分类,纳入适用于活检标本的预后和预测标志物,以形成治疗结局驱动的分类。
研究设计与样本
- 综述,讨论肺NEN分类中的关键临床病理问题及信息性分子标志物。
主要发现
- 活检标本诊断困难,转移性类癌核分裂率可从典型向非典型及高级别NEN升高,进一步增加诊断复杂性。
- 有限样本量可因缺乏神经内分泌形态而漏诊LCNEC。
- 对LCNEC的基因组研究和标志物研究提示,napsin A联合神经内分泌标志物可能有帮助。
关键数值与推荐
- 讨论问题包括低级别NEN根治性切除后首选结局指标(如总生存或无复发生存间期)。
- 讨论WHO分类联合Ki-67增殖指数及OTP、CD44等分子标志物是否改善低级别NEN预后判断。
- 讨论活检标本中典型与非典型类癌诊断在局部和转移性疾病中的价值。
- 讨论形态学分离LCNEC与SCLC的(不)相关性及RB1基因、pRb蛋白或转录因子NEUROD1、ASCL1、POU2F3、YAP1(NAPY)预测全身治疗结局的价值。
- 讨论活检标本中准确分离LCNEC与NSCLC是否需要额外诊断标准。
临床怎么用
- 临床决策需考虑活检标本诊断肺NEN的困难及转移性类癌核分裂率升高的可能。
- 对活检标本可关注Ki-67、OTP、CD44、RB1/pRb、NAPY转录因子及napsin A联合神经内分泌标志物的潜在价值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Diagnosing a pulmonary neuroendocrine neoplasm (NEN) may be difficult, challenging clinical decision making. In this review, the following key clinical and pathologic issues and informative molecular markers are being discussed: (1) What is the preferred outcome parameter for curatively resected low-grade NENs (carcinoid), for example, overall survival or recurrence-free interval? (2) Does the WHO classification combined with a Ki-67 proliferation index and molecular markers, such as OTP and CD44, offer improved prognostication in low-grade NENs? (3) What is the value of a typical versus atypical carcinoid diagnosis on a biopsy specimen in local and metastatic disease? Diagnosis is difficult in biopsy specimens and recent observations of an increased mitotic rate in metastatic carcinoid from typical to atypical and high-grade NEN can further complicate diagnosis. (4) What is the (ir)relevance of morphologically separating large cell neuroendocrine carcinoma (LCNEC) SCLC and the value of molecular markers (RB1 gene and pRb protein or transcription factors NEUROD1, ASCL1, POU2F3, or YAP1 [NAPY]) to predict systemic treatment outcome? (5) Are additional diagnostic criteria required to accurately separate LCNEC from NSCLC in biopsy specimens? Neuroendocrine morphology can be absent owing to limited sample size leading to missed LCNEC diagnoses. Evaluation of genomic studies on LCNEC and marker studies have identified that a combination of napsin A and neuroendocrine markers could be helpful. Hence, to improve clinical practice, we should consider to adjust our NEN classification incorporating prognostic and predictive markers applicable on biopsy specimens to inform a treatment outcome-driven classification.
引用
- Derks JL, Rijnsburger N, Hermans BCM, et al. Clinical-Pathologic Challenges in the Classification of Pulmonary Neuroendocrine Neoplasms and Targets on the Horizon for Future Clinical Practice. J Thorac Oncol. 2021. PMID: 34139363. doi:10.1016/j.jtho.2021.05.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。